CXCR4 and non-small cell lung carcinoma: In contrast, Blayney et al. evaluated Plinabulin as an alternative mobilizing agent, finding that it effectively mobilizes CD34+ hematopoietic cells without significantly inhibiting CXCR4, making it a viable option for NSCLC patients unresponsive to G-CSF-based mobilization (Blayney et al., 2018).